These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 27410239

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL, Winiecki S, Lewis P, Shimabukuro TT, Cano M.
    Vaccine; 2015 Nov 27; 33(48):6684-8. PubMed ID: 26518405
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, Shimabukuro TT.
    Vaccine; 2014 Nov 12; 32(48):6499-504. PubMed ID: 25258101
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
    Miller ER, Lewis P, Shimabukuro TT, Su J, Moro P, Woo EJ, Jankosky C, Cano M.
    Hum Vaccin Immunother; 2018 Nov 12; 14(8):1963-1969. PubMed ID: 29580194
    [Abstract] [Full Text] [Related]

  • 7. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, Stewart B, Markowitz LE, Shimabukuro TT.
    Vaccine; 2018 Mar 20; 36(13):1781-1788. PubMed ID: 29477308
    [Abstract] [Full Text] [Related]

  • 8. Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015.
    Haber P, Arana J, Pilishvili T, Lewis P, Moro PL, Cano M.
    Vaccine; 2016 Dec 07; 34(50):6330-6334. PubMed ID: 27836437
    [Abstract] [Full Text] [Related]

  • 9. Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013.
    Miller ER, Moro PL, Cano M, Lewis P, Bryant-Genevier M, Shimabukuro TT.
    Vaccine; 2016 May 27; 34(25):2841-6. PubMed ID: 27087150
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.
    MMWR Surveill Summ; 2003 Jan 24; 52(1):1-24. PubMed ID: 12825543
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018.
    McNeil MM, Paradowska-Stankiewicz I, Miller ER, Marquez PL, Seshadri S, Collins LC, Cano MV.
    Vaccine; 2019 Oct 16; 37(44):6760-6767. PubMed ID: 31548014
    [Abstract] [Full Text] [Related]

  • 14. Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.
    Myers TR, McNeil MM, Ng CS, Li R, Lewis PW, Cano MV.
    Vaccine; 2017 Mar 27; 35(14):1758-1763. PubMed ID: 28262331
    [Abstract] [Full Text] [Related]

  • 15. Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016.
    Myers TR, McNeil MM, Ng CS, Li R, Marquez PL, Moro PL, Omer SB, Cano MV.
    Vaccine; 2020 Sep 11; 38(40):6291-6298. PubMed ID: 32747215
    [Abstract] [Full Text] [Related]

  • 16. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
    Haber P, Moro PL, Ng C, Lewis PW, Hibbs B, Schillie SF, Nelson NP, Li R, Stewart B, Cano MV.
    Vaccine; 2018 Jan 25; 36(4):559-564. PubMed ID: 29241647
    [Abstract] [Full Text] [Related]

  • 17. Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012.
    Haber P, Moro PL, Cano M, Vellozzi C, Lewis P, Woo EJ, Broder K.
    J Pediatric Infect Dis Soc; 2015 Sep 25; 4(3):205-13. PubMed ID: 26407428
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.
    Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, Shimabukuro TT.
    Clin Infect Dis; 2015 May 15; 60(10):e58-65. PubMed ID: 25637587
    [Abstract] [Full Text] [Related]

  • 20. Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.
    Haber P, Moro PL, Cano M, Lewis P, Stewart B, Shimabukuro TT.
    Vaccine; 2015 Apr 15; 33(16):1987-92. PubMed ID: 25678241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.